The clinical performance is complex and often involves multiple systems. Early identification and standardization of clinical treatments are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological evaluations.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many blood tumor diseases that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of limited skin polymorphism. The platform serves a team of experts at home and abroad in the field of blood tumor services linked to the China International Medical Service System, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.